Stock Analiz

Viridian Therapeutics, Inc.\DE (VRDN) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Viridian Therapeutics, Inc.\DE’s revenue went from $3M in fiscal 2016 to $71M in fiscal 2025, growth of about 39.8% a year.

Net income in fiscal 2025 was -$343M, a net margin of -483.6%; the best year in this period was 2016 with -$17M.

Over the twelve months to September 30, 2026, revenue was $26M and net income -$454M.

Free cash flow was -$277M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 277315% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $3M162017: $4M172018: $8M182019: $4M192020: $1M202021: $3M212022: $2M222023: $314000232024: $302000242025: $71M25$71M
Net income
2016: -$17M162017: -$27M172018: -$33M182019: -$42M192020: -$111M202021: -$79M212022: -$130M222023: -$238M232024: -$270M242025: -$343M25-$343M
Free cash flow
2016: -$15M162017: -$28M172018: -$27M182019: -$36M192020: -$30M202021: -$55M212022: -$95M222023: -$185M232024: -$233M242025: -$277M25-$277M
EPS (diluted)
2016: $-423.15162017: $-20.70172018: $-16.50182019: $-20.04192020: $-31.13202021: $-6.66212022: $-4.05222023: $-5.31232025: $-3.0225$-3.02

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$26M$71M$302000$314000$2M$3M$1M$4M$8M$4M$3M
Gross profit——————————$929000
Operating income-$469M-$363M-$299M-$254M-$134M-$80M-$110M-$42M-$33M-$27M-$17M
Net income-$454M-$343M-$270M-$238M-$130M-$79M-$111M-$42M-$33M-$27M-$17M
EPS (diluted)$-4.38$-3.02—$-5.31$-4.05$-6.66$-31.13$-20.04$-16.50$-20.70$-423.15
R&D$309M$339M$238M$160M$101M$57M$28M$35M$30M$20M$14M
Revenue growth—+23359.9%−3.8%−82.3%−40.2%+182.2%−76.5%−46.8%+109.5%+15.1%−39.1%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$342M-$276M-$232M-$184M-$94M-$55M-$30M-$36M-$27M-$28M-$15M
Capital spending-$2M-$495000-$511000-$898000-$797000-$338000-$42000-$84000-$445000-$246000-$250000
Free cash flow-$343M-$277M-$233M-$185M-$95M-$55M-$30M-$36M-$27M-$28M-$15M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks——————————$2000
Stock-based pay$60M$44M$42M$67M$20M$14M$4M$4M$4M$2M$198000

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$875M$718M$477M$425M$197M$128M$27M$62M$47M$22M
Debt—$53M$23M$22M$6M$2M$455000$9M$10M$10M$5M
Equity—$722M$672M$442M$395M$188M$120M$16M$51M$39M-$62M
Total assets—$899M$742M$490M$435M$204M$131M$30M$66M$52M$25M
Shares (diluted)105M114M—45M32M12M4M2M2M1M0M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin——————————26.7%
Operating margin-1781.4%-512.9%-99018.2%-81035.0%-7579.2%-2690.8%-10512.4%-941.0%-394.5%-662.8%-488.6%
Net margin-1724.1%-483.6%-89387.1%-75711.5%-7329.2%-2680.2%-10544.3%-938.6%-390.0%-662.3%-496.8%
FCF margin-1305.4%-390.8%-77096.0%-58938.9%-5340.6%-1853.5%-2840.1%-810.1%-325.4%-709.8%-431.6%
ROIC—-37.0%-34.0%-43.3%-26.4%-33.2%-72.4%-135.6%-42.4%-43.2%—
ROE—-47.4%-40.2%-53.8%-32.9%-42.3%-92.2%-265.8%-63.7%-68.8%27.9%

Frequently asked questions

What is Viridian Therapeutics, Inc.\DE’s annual revenue?

$71M in fiscal 2025 and $26M over the twelve months to September 30, 2026.

How much profit does Viridian Therapeutics, Inc.\DE make?

Net income was -$343M in fiscal 2025 (net margin -483.6%).

Is Viridian Therapeutics, Inc.\DE’s revenue growing?

Yes: revenue rose 23359.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.